Robert Hills Crohns Disease Story

Robert Hills Crohns Disease Story

Robert Hills Crohns Disease Story from Diagnosis to Summit

Facing Everest

In 2008, Robert Hill attempted to summit Mount Everest to raise awareness of Crohn’s disease. But trouble struck early in the climb, jeopardizing Robert’s dream of becoming the first person with an ostomy to scale the world’s highest mountain.

Bad Memories

Robert was flown back to his home in Vancouver, British Columbia, to be treated by his own medical team. His doctor determined that Robert had suffered an obstructed bowel. The pains on Everest brought back terrible memories of his Crohn’s diagnosis at age 23.

Robert Hills Crohns Disease Story

Robert Hills Crohns Disease Story

The Body Attacks Itself

Robert dwindled from a robust 185 pounds to a skeletal 105. At his weakest, the once avid climber, who had been taught as a boy to scale rocks by his father, could barely make it upstairs. It had become an exhausting process: Hold on to the handrail. Step up. Lift the other leg. Rest. His muscle mass gone, every step was painful.

Crohn’s disease is a chronic autoimmune disease that can affect any part of the digestive tract. The body essentially attacks itself, triggering intense inflammation that wears away digestive organs, particularly the intestine. The cause is still a mystery, although research suggests that genetic and environmental factors play a role. Roughly 700,000 Americans live with Crohn’s disease. There is no known cure.

What is Crohn’s Disease?

Crohn’s disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract.

When reading about inflammatory bowel diseases, it is important to know that Crohn’s disease is not the same thing as ulcerative colitis, another type of IBD. The symptoms of these two illnesses are quite similar, but the areas affected in the gastrointestinal tract (GI tract) are different.

Crohn’s most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus. Ulcerative colitis is limited to the colon, also called the large intestine.

Experience Robert Hill’s Amazing Story Living with Crohn’s from Diagnosis to Summit

Robert Hill Amazing Story Living with Crohns

Crohns Disease Risk Psoriasis

Crohns Disease Risk Psoriasis

Crohns Disease Risk Psoriasis, Psoriasis increases the risk of Crohn’s disease in women. Research revealed that women with psoriasis have a fourfold risk of developing Crohn’s disease, based on data from two large cohort studies. On the other hand, psoriasis did not increase the risk of ulcerative colitis in either cohort.

Reversing the association, an alternative study found a 13 percent psoriasis prevalence among patients with inflammatory bowel disease (IBD).

Crohns Disease Risk Psoriasis

Crohns Disease Risk Psoriasis

Researcher Abrar A. Qureshi said, “Certainly, this is a preliminary study, but it does begin to make sense because we are seeing patients with Crohn’s disease and psoriasis overlap. The inflammatory pathways that have been identified at the genetic level in genome-wide association studies make sense as well, because there is overlap in the interleukin-12 and interleukin-23 pathways in psoriasis and Crohn’s disease.”

The studies reveal similar pathways in IBD and psoriasis. Both Crohn’s disease and psoriasis are Th1-mediated conditions (which means, the immune system uses Th1 helper cells to eliminate what it mistakenly deems as invaders inside our cells). Ulcerative colitis is primarily mediated through the Th2 pathway (Th2 helpers work outside of the cells).

The researchers analyzed 174,646 participants in the Nurses’ Health Study (NHS) and NHS II. The researchers identified nearly 4,400 cases of psoriasis in the combined studies. Psoriasis patients were generally older, had a higher body mass index, were less active, consumed more alcohol, and were more likely to be smokers.

During follow-up (1996 to 2008 in NHS and 1991 to 2007 in NHS II), 423 study participants developed Crohn’s disease or ulcerative colitis.

Prevalence of psoriasis was four to six times greater in IBD patients than the estimated prevalence in the general public – which is two to three percent.

Read more: Risk Psoriasis

Specialists Building Medical Homes

Specialists Building Medical Homes

Specialists Can Build Their Own Medical Homes, Two years ago, Lawrence Kosinski, M.D., would tell people there’s no place like a specialty intensive medical home. Now he has the data to back it up.

Kosinski is managing partner of Illinois Gastroenterology Group, the state’s largest such practice, which has reduced spending for its patients with Crohn’s disease by almost 10 percent in 10 months.

“We’ve kept the patients healthier and kept them out of the hospital,” Kosinski says. “We’re showing strong positive results.”

With support from the Health Care Service Corp.-affiliate Blue Cross and Blue Shield of Illinois, Kosinski and IGG operate a specialty medical home whose foundation is technology-assisted patient engagement. The model has reduced hospital costs for patients with Crohn’s disease by 57 percent and emergency department costs by 53 percent.

Kosinski was serving as chairman of the American Gastroenterological Association’s practice management and economics committee when he saw how colonoscopies accounted for 54 percent of a typical gastroenterology practice’s income. He became concerned that his specialty relied too heavily on one procedure.

It was critical that gastroenterologists find additional ways to apply their special skills, Kosinski says. A study of two years’ worth of BCBSIL claims data on 21,000 patients suggested Crohn’s treatment could be where they might make the biggest difference.

The insurer was spending $240 million on Crohn’s treatment or $11,000 per patient, with half of it going for inpatient stays and often for “devastating complications” such as infections, bleeding, bowel obstructions or fistulas. About 10 percent of the costs were spent on pharmaceuticals and only 3.8 percent was going to gastroenterologists.

Read more: Specialists Can Build Their Own Medical Homes

Canada First Crohns Disease Center

Canada First Crohns Disease Center

Canada First Crohns Disease Center

Canada recently announced the nation’s first network for Crohn’s disease and ulcerative colitis patient care and research: Promoting Access and Care through Centres of Excellence (PACE). It is the most extensive Canadian collaboration for adults living with the two main manifestations of inflammatory bowel disease (IBD).

PACE will host a combination of independent and collaborative research that will take place over four years. During the first year, each center will drive their research, and in the following three years, all centers will collaborate to develop their specific strengths. Crohn’s and Colitis Canada will provide each center with $500,000.

According to a press release, Dr. Remo Panaccione, an international expert in IBD and the director of the University of Calgary’s IBD clinic since 2001, is one of five expert clinicians involved in the project. He will lead the Calgary center with Dr. Robert Fedorak, from the University of Alberta.

Canada First Crohns Disease Center

Canada First Crohns Disease Center

“The vision of PACE and the Calgary Inflammatory Bowel Disease Research Centre is to improve the quality of life of our patients with IBD —we will work to identify and target immune pathways in order to develop personalized therapies and biomarkers for disease surveillance,” said Panaccione who is also a member of the chronic disease-focused Snyder Institute for Chronic Diseases in the Cumming School of Medicine.

Calgary will be in charge of elevating the standard of care’s consistency

stablishing standard clinical practice procedures and treatments across the country. Calgary’s team will work to introduce technological alternatives for integrating best practices into healthcare.

The University of Calgary is teamed with the University of Alberta to develop standardized treatments, explicitly addressing the extended use of steroids. Steroids reduce inflammation and bring about improvement, but long-term use can also bring significant side effects. The application should be kept at a minimum.

“Our priority is reducing steroid use in Crohn’s disease and ulcerative colitis patients,” Panaccione said. “Three-quarters of patients referred to a specialist are on steroid treatment and our work will address this issue.”

Each year, Alberta sees 1,000 new IBD diagnoses. With 20,000 known cases in the province, when ranked by population, Alberta has among the highest levels of IBD burden in the world.

Read more: Canada First Crohns Disease Center

Canada First Crohns Disease Center

Seantrel Henderson Crohns Disease

Seantrel Henderson Crohns Disease

Seantrel Henderson Crohns Disease

With training camp less than a month away, one of the biggest questions surrounding the Buffalo Bills is who they’re going to have at right tackle come Week 1. It’s been a part of their roster that has been a question mark for a while.

Seantrel Henderson Crohns Disease

Seantrel Henderson Crohns Disease

Last season, Seantrel Henderson carried most of the load and did a decent job of it. However, his health concerns are an issue and it’s unclear if we have anyone else to replace him. If you don’t recall, Henderson was our 2014 seventh-round draft pick that was diagnosed with Crohn’s disease well into last season. He ended up missing the final five games of the season and is still not sure of a timetable on his return.

For most of this offseason, not much was said about their plans with Seantrel. It was, and still is, kind of just a waiting game. However, Bills’ GM Doug Whaley spat out some words of hope and optimism to Bills fans during an interview with WGR 550. Whaley stated that the Bills have heard good news on Henderson’s health and although they still aren’t sure on a timetable, he is moving in the right direction.

So far, the Bills have a few options to consider. The first is to just keep him on the roster and let him heal, hoping he comes back within the first few games of the season. The second, which is growing in popularity, is to place him on the NFI list and give him guaranteed time to heal.

The NFI list is the Non-Football Injury list, which is similar to the Physically Unable to Perform. While the PUP indicates they have an injury sustained while playing football, the NFI regards injuries and illnesses that happen outside of football. Like the PUP list, placing a player on the NFI list will keep him out of the first 6 weeks indefinitely.

The proto placing him on the NFI list is that we gain a roster spot, which we could use to replace him until he recovers. Also, it gives him more than enough time to recover and be ready to play start when he comes back. However, as I said above, we would be without him for at least six weeks. After those six weeks, the Bills can decide what they want to do with him. They can either activate him to the roster or keep him on the list. If he is kept on the list, he will be out for the rest of the season.

Read more: Seantrel Henderson Progress With Crohns Disease

Seantrel Henderson Crohns Disease